Ekso Bionics Holdings, Inc. (EKSO)

In October 2025, Ekso Bionics announced a $3.7 million registered direct offering and reported Q3 2025 financial results. In December 2025, Applied Digital Cloud Corporation signed a letter of intent to acquire Ekso Bionics in a reverse merger, and Ekso Bionics became the exclusive U.S. distributor for MediTouch's BalanceTutor. In January 2026, Ekso Bionics announced and closed a private placement of Series B preferred stock and warrants. In February 2026, insider Daniel Asher purchased common stock, and the company's Board approved amendments to its bylaws related to the proposed transaction with Applied Digital. In March 2026, Ekso Bionics filed its Form 10-K, with the auditor expressing doubt about the company's ability to continue as a going concern. The stock experienced significant price growth over the past year.

Specific data on demand seasonality for Ekso Bionics' products is limited. Seeking Alpha indicates mean and median monthly returns for EKSO to identify seasonal patterns. Intellectia AI's seasonality analysis suggests some monthly variations in stock performance. The company's revenue has shown fluctuations year-over-year, but these are not explicitly attributed to seasonal demand.

Ekso Bionics Holdings, Inc. is a robotics company specializing in wearable exoskeleton products that enhance human capabilities. It operates in the Medical Instruments & Supplies industry, serving both healthcare and industrial markets. Key products include EksoNR for neurorehabilitation, Ekso Indego Therapy for therapy and training, Ekso Indego Personal for personal use, Ekso EVO for industrial use, and the MediTouch BalanceTutor rehabilitation system. The company operates through Enterprise Health and Personal Health segments.

Ekso Bionics is based in the United States, with its headquarters in San Rafael, California, and serves customers globally across the Americas, EMEA, and APAC regions. The company established a regional headquarters in Freiburg, Germany, in 2015 to strengthen its European presence. Its products are utilized in over 500 rehabilitation centers worldwide.

Ekso Bionics is known as a pioneer in exoskeleton technology. Positive events include the launch of the EksoHealth Personal Program, strategic partnerships like the MediTouch distributorship, and acceptance into the NVIDIA Connect Program. Positive media mentions, such as the CEO and Director of Clinical Operations discussing Ekso Indego on "Health Uncensored with Dr. Drew," contribute to brand visibility. Potentially negative events include the proposed reverse merger with Applied Digital, the auditor's doubt about the company's ability to continue as a going concern, and a reported revenue decline in Europe.

As of March 27, 2026, Ekso Bionics Holdings, Inc. has 28 institutional owners and shareholders holding 6.42% of the stock. Major institutional investors include Dba Trading, Llc, Vanguard Group Inc, Geode Capital Management, Llc, Cresset Asset Management, LLC, Scientech Research LLC, and BlackRock, Inc. Key individual owners include Daniel Asher and Chickasaw Nation Industries Inc.